SCHEMBL14256642

SCHEMBL14256642

O=C1OCCN1Nc1nc(NCc2ccccc2Sc2ccccc2CO)nc2ccccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 4/20 0.38
▸ ACHE P22303 4/20 0.38
▸ RAD52 P43351 1/20 0.37
▸ LMNA P02545 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ UBE2N P61088 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ RCE1 Q9Y256 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ RECQL P46063 1/20 0.35
▸ PIK3R1 P27986 2/20 0.34
▸ PIK3CA P42336 2/20 0.34
▸ MTOR P42345 2/20 0.34
▸ BCHE P06276 1/20 0.34
▸ ELANE P08246 1/20 0.34
▸ IFNAR1 P17181 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14256643 0.83 PDE5A (0.41) ACHERAD52LMNAKDM4EALDH1A1
SCHEMBL14256646 0.80 RAD52 (0.40) APPACHERAD52LMNAKDM4E
SCHEMBL14468031 0.79 SMN1; SMN2 (0.34) APPACHELMNAKMT2ASMN1; SMN2
SCHEMBL14266698 0.78 RAD52 (0.35) APPACHERAD52LMNAKDM4E
SCHEMBL14256650 0.77 CYP1A2 (0.44) LMNAKDM4EALDH1A1MAPTKMT2A
SCHEMBL14412274 0.76 LMNA (0.40) APPACHERAD52LMNAKDM4E
SCHEMBL14412252 0.76 APP (0.40) APPACHERAD52LMNAKDM4E
SCHEMBL14256700 0.75 APP (0.46) APPACHERAD52LMNAKDM4E
SCHEMBL14256691 0.75 LMNA (0.55) LMNAKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL14256685 0.74 PDE5A (0.49) APPACHERAD52LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058312-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2008-03-06 — — US disclosed
US-20080058312-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2008-03-06 — — US disclosed
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2007-09-13 — — US disclosed
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2007-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity HGF, MET, HDGF APP 3034/4885ACHE 3271/4885RAD52 4485/4885
US-20080058312-A1 Modulators of hepatocyte growth factor/c-Met activity HGF, MET, HDGF APP 2885/4885ACHE 3315/4885RAD52 4489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback